Elevance Health’s $470M Volume Drops 30% to Rank 240th as Shares Fall 1.16%

On October 9, 2025, , , ranking it 240th among stocks in terms of liquidity. , reflecting a modest but notable pullback in its recent trajectory.

Recent developments highlight shifting dynamics in the health insurance sector. A regulatory update on Medicare Advantage enrollment adjustments has sparked renewed scrutiny of Elevance’s market share, with analysts recalibrating growth expectations. Meanwhile, a strategic pivot toward digital health partnerships has drawn mixed investor sentiment, as the long-term value of these collaborations remains under evaluation. The stock’s performance appears tethered to macroeconomic signals, particularly as rising pressure high-growth healthcare equities.

To execute a precise back-test, several parameters require clarification: the exchange universe for daily-volume rankings, trade entry/exit timing (same-day close vs. next-day open), weighting schemes for portfolio allocation, and whether transaction costs or slippage should be factored in. Price sources must also be confirmed—whether using unadjusted close prices or adjusted series. Once these details are finalized, the strategy can be tested from January 1, 2022, to generate performance metrics and an equity curve for further analysis.